Related Experiment Video
Updated: May 13, 2026
09:31
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Glutamate carboxypeptidase II does not process amyloid-β peptide
František Sedlák1, Pavel Šácha, Miroslava Blechová
1Gilead Sciences, Prague, Czech Republic.
Summary
Glutamate carboxypeptidase II (GCPII) does not degrade amyloid-beta (Aβ) peptides, contrary to recent suggestions. This finding is crucial for developing GCPII inhibitors for neurological disorders without risking increased Alzheimer's disease pathology.
Area of Science:
- Biochemistry
- Neuroscience
- Enzymology
Background:
- Amyloid-beta (Aβ) peptide accumulation is a key factor in Alzheimer's disease pathogenesis.
- Dysregulated amyloid precursor protein processing or inefficient Aβ degradation contributes to Aβ accumulation.
- Glutamate carboxypeptidase II (GCPII) is a metallopeptidase involved in glutamate metabolism and a therapeutic target for neurotoxicity.
Purpose of the Study:
- To investigate the reported Aβ-degrading activity of glutamate carboxypeptidase II (GCPII).
- To determine if GCPII inhibition could inadvertently increase Aβ levels, posing a risk for Alzheimer's disease.
- To clarify the enzymatic function of GCPII in relation to Aβ metabolism.
Main Methods:
- Utilized highly purified recombinant glutamate carboxypeptidase II (GCPII) enzyme.
- Employed synthetic amyloid-beta (Aβ) peptides as substrates.
- Performed prolonged incubation assays with high enzyme-to-substrate ratios.
Main Results:
- No detectable degradation of amyloid-beta (Aβ) by glutamate carboxypeptidase II (GCPII) was observed.
- GCPII homologues also exhibited no Aβ-degrading activity under the tested conditions.
- Results align with the known substrate specificity and structural characteristics of GCPII.
Conclusions:
- Glutamate carboxypeptidase II (GCPII) does not possess amyloid-beta (Aβ) degrading activity.
- The proposed Aβ-degrading function of GCPII is not supported by experimental evidence.
- GCPII inhibitors can be safely explored for therapeutic applications without concerns of exacerbating Alzheimer's disease pathology.
More Related Videos
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Protein Folding Quality Check in the RER
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
01:32Export of Misfolded Proteins out of the ER
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...